Authors
U Lassen, LR Molife, M Sorensen, SA Engelholm, L Vidal, R Sinha, RT Penson, P Buhl-Jensen, E Crowley, Tjornelund, J, P Knoblauch, JS de Bono
Publication date
2010
Journal
Br J Cancer,
Volume
29
Issue
1
Pages
12-17
Description
Background:
This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.
Methods:
Cohorts of three to six patients were treated with escalating doses of belinostat administered intravenously once daily, days 1–5 q21 days; on day 3, carboplatin (area under the curve (AUC) 5) and/or paclitaxel (175 mg m− 2) were administered 2–3 h after the end of the belinostat infusion.
Results:
In all 23 patients received 600–1000 mg m− 2 per day of belinostat with carboplatin and/or paclitaxel. No DLT was observed. The maximal administered dose of belinostat was 1000 mg m− 2 per day for days 1–5, with paclitaxel (175 mg m− 2) and carboplatin AUC 5 administered on day 3. Grade III/IV adverse events were (n;%): leucopenia (5; 22%), neutropenia (7; 30 …
Total citations
Scholar articles
U Lassen, LR Molife, M Sorensen, SA Engelholm… - British journal of cancer, 2010